论文部分内容阅读
目的:探讨降脂导滞胶囊对血脂异常大鼠的调脂作用及机制。方法 :60只大鼠随机分为6组,正常组,模型组,血脂康组,降脂导滞胶囊低、中、高剂量组。除正常组外,其它组大鼠喂高脂饲料,造模成功后灌服相应剂量药物。观察用药后大鼠的血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、脂蛋白脂酶(LPL)、肝脂酶(HL)水平。结果:各大鼠体重随实验时间延长呈现不同程度的增长。自第3周开始,模型组,血脂康组,降脂导滞胶囊低、中、高剂量组大鼠的体重增长有所减缓(P<0.05)。第12周末TC、TG、HDL-C、LDL-C血脂康组,低、中、高剂量组大鼠与正常组、模型组比较均有差异(P<0.01,P<0.05)。第12周末,有序分组资料线性趋势检验分析得出HL、LPL在降脂导滞胶囊各剂量组之间有线性趋势(P<0.05),说明HL、LPL水平的改变与降脂导滞胶囊的剂量有关,存在剂量依赖性。结论:降脂导滞胶囊可以通过激活脂代谢相关酶,调节血清中血脂和脂蛋白的含量,从而治疗高脂血症。
Objective: To investigate the lipid-lowering effect and mechanism of Jiangzhi Daozhi Capsule on dyslipidemia rats. Methods: Sixty rats were randomly divided into six groups: normal group, model group, Xuezhikang group, low fat, medium and high dose of lipid lowering guide capsule. In addition to the normal group, other groups of rats fed high-fat diet, the model was successfully fed the appropriate dose of medicine. The levels of serum TC, TG, HDL-C, LDL-C, LPL, Liver lipase (HL) levels. Results: The body weight of rats increased with experimental time to varying degrees. Since the third week, the model group, Xuezhikang, lipid-lowering guide capsule low, medium and high dose group rats weight gain has slowed (P <0.05). At the end of the twelfth week, TC, TG, HDL-C and LDL-C in Xuezhikang group were lower than those in normal group and model group (P <0.01, P <0.05). At the end of the twelfth week, linear trend test of ordered grouping data showed that HL and LPL had a linear tendency (P <0.05) between each dosage group of lipid-lowering guide capsule, indicating that the changes of HL and LPL level were similar to those of lipid- Of the dose, there is dose-dependent. Conclusion: Jiangzhizhiyou Capsule can treat hyperlipidemia by activating lipase-related enzymes and regulating serum lipids and lipoproteins.